Effect of Statin Use on Aldosterone Secretion

Model scores of the 29,894 trials active now.

Model score 6% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (918 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: coronarydiseasestatinstrokeiv
  Phrases that lowered it: screeningmmhgkgmass indexbody mass
• Primary purpose: other (lowers risk) · Design
• Sponsor's past termination rate: 10.8% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 8.0% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 72 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 165949 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 23667 (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 72.4% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 3 (lowers risk) · Design
• Blinding: double (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production NCT02871648 · started 2016 · scored riskier than 4% of active trials completed
• Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED) NCT00935259 · started 2009 · scored riskier than 32% of active trials completed
• Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study NCT00728910 · started 2008 · scored riskier than 40% of active trials completed
• Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis NCT02968810 · started 2017 · scored riskier than 94% of active trials completed
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin NCT01218204 · started 2010 · scored riskier than 17% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.